Salesforce, OpenAI CEOs invest in diagnostics company

Must read

Salesforce’s Benioff and OpenAI’s Altman invest in Vital Biosciences

Salesforce CEO Marc Benioff and OpenAI CEO Sam Altman are among the investors in Vital Biosciences, a company developing a point-of-care diagnostic test, according to a news release.

The $18 million Series A funding round announced Tuesday, led by Lachy Groom and Northpond Ventures, will support late-stage product development and clinical studies planned this year, Vital Biosciences said.

Proprio finalizes round focused on commercialization

Surgical technology company Propio announced Thursday that it raised $43 million from a Series B funding round.

Propio’s software uses light field technology and artificial intelligence to generate 3D visualizations of surgeries. The money will be used for marketing, the company said.

Sigma Group led the round while medical technology investor Bird B made the largest investment.

RapidAI closes $75 million Series C

RapidAI, a clinical decision support and technology company, announced a $75 million Series C round led by Vista Credit Partners, a subsidiary of the private equity firm.

The company declined to disclose whether some or all the funding is composed of debt financing.

RapidAI offers products for stroke, aneurysm and pulmonary embolism and intends to apply the investments to develop products for additional disease states and to fund new market expansions, according to a news release.

More articles

Latest article